364 related articles for article (PubMed ID: 33467756)
21. [Neoadjuvant treatment in osteosarcomas].
Kalifa C; Brugières L; Le Deley MC
Bull Cancer; 2006 Nov; 93(11):1115-20. PubMed ID: 17145581
[TBL] [Abstract][Full Text] [Related]
22. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
Bacci G; Ferrari S; Longhi A; Picci P; Mercuri M; Alvegard TA; Saeter G; Donati D; Manfrini M; Lari S; Briccoli A; Forni C;
J Chemother; 2002 Apr; 14(2):198-206. PubMed ID: 12017378
[TBL] [Abstract][Full Text] [Related]
23. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.
Goorin AM; Schwartzentruber DJ; Devidas M; Gebhardt MC; Ayala AG; Harris MB; Helman LJ; Grier HE; Link MP;
J Clin Oncol; 2003 Apr; 21(8):1574-80. PubMed ID: 12697883
[TBL] [Abstract][Full Text] [Related]
24. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Whelan JS; Bielack SS; Marina N; Smeland S; Jovic G; Hook JM; Krailo M; Anninga J; Butterfass-Bahloul T; Böhling T; Calaminus G; Capra M; Deffenbaugh C; Dhooge C; Eriksson M; Flanagan AM; Gelderblom H; Goorin A; Gorlick R; Gosheger G; Grimer RJ; Hall KS; Helmke K; Hogendoorn PC; Jundt G; Kager L; Kuehne T; Lau CC; Letson GD; Meyer J; Meyers PA; Morris C; Mottl H; Nadel H; Nagarajan R; Randall RL; Schomberg P; Schwarz R; Teot LA; Sydes MR; Bernstein M;
Ann Oncol; 2015 Feb; 26(2):407-14. PubMed ID: 25421877
[TBL] [Abstract][Full Text] [Related]
25. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience.
Saeter G; Wiebe T; Wiklund T; Monge O; Wahlqvist Y; Engström K; Forestier E; Holmström T; Stenwig AE; Willén H; Brosjö O; Follerås G; Alvegård TA; Strander H
Acta Orthop Scand Suppl; 1999 Jun; 285():74-82. PubMed ID: 10429627
[No Abstract] [Full Text] [Related]
27. [Progress and stagnation in chemotherapy protocols for primary osteosarcoma].
Delépine N; Alkallaf S; Cornille H; Markowska B; Delépine G
Ann Med Interne (Paris); 2003 Feb; 154(1):12-24. PubMed ID: 12746655
[TBL] [Abstract][Full Text] [Related]
28. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
29. Limb-sparing in patients with non-metastatic high-grade osteosarcoma.
Samardziski M; Zafiroski G; Tolevska C; Zafirova-Ivanovska B; Kostadinova-Kunovska S; Kalicanin-Markovska M
J BUON; 2009; 14(1):63-9. PubMed ID: 19373949
[TBL] [Abstract][Full Text] [Related]
30. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Bielack SS; Smeland S; Whelan JS; Marina N; Jovic G; Hook JM; Krailo MD; Gebhardt M; Pápai Z; Meyer J; Nadel H; Randall RL; Deffenbaugh C; Nagarajan R; Brennan B; Letson GD; Teot LA; Goorin A; Baumhoer D; Kager L; Werner M; Lau CC; Sundby Hall K; Gelderblom H; Meyers P; Gorlick R; Windhager R; Helmke K; Eriksson M; Hoogerbrugge PM; Schomberg P; Tunn PU; Kühne T; Jürgens H; van den Berg H; Böhling T; Picton S; Renard M; Reichardt P; Gerss J; Butterfass-Bahloul T; Morris C; Hogendoorn PC; Seddon B; Calaminus G; Michelagnoli M; Dhooge C; Sydes MR; Bernstein M;
J Clin Oncol; 2015 Jul; 33(20):2279-87. PubMed ID: 26033801
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma.
Weiner MA; Harris MB; Lewis M; Jones R; Sherry H; Feurer EJ; Johnson J; Lahman E
Cancer Treat Rep; 1986 Dec; 70(12):1431-2. PubMed ID: 3466693
[No Abstract] [Full Text] [Related]
32. Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.
Patel SJ; Lynch JW; Johnson T; Carroll RR; Schumacher C; Spanier S; Scarborough M
Am J Clin Oncol; 2002 Oct; 25(5):489-95. PubMed ID: 12393991
[TBL] [Abstract][Full Text] [Related]
33. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response.
Ferrari S; Mercuri M; Picci P; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Longhi A; Rimondini S; Donati D; Manfrini M; Ruggieri P; Biagini R; Bacci G
Tumori; 1999; 85(6):458-64. PubMed ID: 10774566
[TBL] [Abstract][Full Text] [Related]
34. EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.
Ferrari S; Bielack SS; Smeland S; Longhi A; Egerer G; Sundby Hall K; Donati D; Kevric M; Brosjö O; Comandone A; Werner M; Monge O; Palmerini E; Berdel WE; Bjerkehagen B; Paioli A; Lorenzen S; Eriksson M; Gambarotti M; Tunn PU; Jebsen NL; Cesari M; von Kalle T; Ferraresi V; Schwarz R; Bertulli R; Kasparek AK; Grignani G; Krasniqi F; Sorg B; Hecker-Nolting S; Picci P; Reichardt P
Tumori; 2018; 104(1):30-36. PubMed ID: 29218692
[TBL] [Abstract][Full Text] [Related]
35. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.
Hattinger CM; Michelacci F; Sella F; Magagnoli G; Benini S; Gambarotti M; Palmerini E; Picci P; Serra M; Ferrari S
Histopathology; 2015 Sep; 67(3):338-47. PubMed ID: 25600168
[TBL] [Abstract][Full Text] [Related]
36. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial.
Ferguson WS; Harris MB; Goorin AM; Gebhardt MC; Link MP; Shochat SJ; Siegal GP; Devidas M; Grier HE
J Pediatr Hematol Oncol; 2001; 23(6):340-8. PubMed ID: 11563767
[TBL] [Abstract][Full Text] [Related]
37. Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies.
Bacci G; Picci P; Ferrari S; Casadei R; Brach Del Prever A; Tienghi A; Mancini A
J Chemother; 1993 Aug; 5(4):237-46. PubMed ID: 8229152
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen.
Bacci G; Ferrari S; Bertoni F; Mercuri M; Forni C; Sottili S; Gasbarrini A; Tienghi A; Cesari M; Campanacci M
J Chemother; 1997 Aug; 9(4):293-9. PubMed ID: 9269611
[TBL] [Abstract][Full Text] [Related]
39. Is it important to maintain high-dose intensity chemotherapy in the treatment of adults with osteosarcoma?
Kushnir I; Kolander Y; Bickels J; Gortzak Y; Flusser G; Issakov J; Merimsky O
Med Oncol; 2014 May; 31(5):936. PubMed ID: 24719037
[TBL] [Abstract][Full Text] [Related]
40. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
